Sugi Predict

Sugi Predict / Compounds / SCHEMBL23536683

SCHEMBL23536683

SCHEMBL23536683

COC(=O)c1ncc(N2CCN(C(=O)OC(C)(C)C)CC2)cn1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 8/20 0.53
▸ MAPT P10636 3/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ TSHR P16473 1/20 0.52
▸ LMNA P02545 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ CKS1B P61024 1/20 0.47
▸ SKP1 P63208 1/20 0.47
▸ SKP2 Q13309 1/20 0.47
▸ F13A1 P00488 2/20 0.47
▸ TGM2 P21980 2/20 0.47
▸ TGM1 P22735 2/20 0.47
▸ NAMPT P43490 1/20 0.46
▸ NR1H2 P55055 1/20 0.46
▸ CYP2C19 P33261 1/20 0.45
▸ WNT3A P56704 1/20 0.45
▸ PTPN11 Q06124 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30984699 0.85 CYP11B2 (0.53) GPR119MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL26683764 0.84 GPR119 (0.60) GPR119MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL14802410 0.84 SMN1; SMN2 (0.60) GPR119MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL29913781 0.84 SMN1; SMN2 (0.60) GPR119MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL20311204 0.83 GPR119 (0.57) GPR119MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL31111540 0.83 GPR119 (0.57) GPR119MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL25544561 0.83 CKS1B (0.47) GPR119MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL18204085 0.82 GPR119 (0.56) GPR119MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL16892111 0.82 GPR119 (0.56) GPR119MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL16892019 0.82 PIK3CA (0.59) GPR119MAPTSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260053796-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS INC (US) 2026-02-26 — — US disclosed
US-12427144-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2025-09-30 — — US disclosed
US-20250059138-A1 CHEMICAL LINKERS SIGMA-ALDRICH CHEMICALS PRIVATE LIMITED (IN) 2025-02-20 — — US disclosed
EP-4452945-A2 CHEMICAL LINKERS Sigma-Aldrich Co. LLC (US) 2024-10-30 — — EP disclosed
CN-118434717-A Chemical joint 西格马-奥尔德里奇有限责任公司 2024-08-02 — — CN disclosed
CN-118059104-A Compounds and methods for targeted degradation of androgen receptor 阿尔维纳斯运营股份有限公司 2024-05-24 — — CN disclosed
US-20240131023-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2024-04-25 — — US disclosed
CN-115175901-B Compounds and methods for targeted degradation of androgen receptor 阿尔维纳斯运营股份有限公司 2024-03-22 — — CN disclosed
US-11883393-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2024-01-30 — — US disclosed
WO-2023122481-A2 CHEMICAL LINKERS SIGMA-ALDRICH CO. LLC (US) 2023-06-29 — — WO disclosed
EP-4077309-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas Operations, Inc. (US) 2022-10-26 — — EP disclosed
CN-115175901-A Compounds and methods for targeted degradation of androgen receptor 阿尔维纳斯运营股份有限公司 2022-10-11 — — CN disclosed
US-20210332036-A1 PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS REGENACY PHARMACEUTICALS LLC (US) 2021-10-28 — — US disclosed
US-20210196710-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2021-07-01 — — US disclosed
US-20210196710-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2021-07-01 — — US disclosed
WO-2021127443-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. (US) 2021-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210332036-A1 PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS HDAC1, HDAC2, HDAC11 GPR119 2743/4885MAPT 1952/4885SMN1; SMN2 1802/4885
US-20260053796-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, NR5A1, KLK3 GPR119 1070/4885MAPT 4164/4885SMN1; SMN2 4302/4885
US-12427144-B2 Compounds and methods for the targeted degradation of androgen receptor AR, KLK3, ACP3 GPR119 1278/4885MAPT 2786/4885SMN1; SMN2 4176/4885
US-20250059138-A1 CHEMICAL LINKERS MDM2, ADRM1, USP36 GPR119 4392/4885MAPT 1635/4885SMN1; SMN2 3175/4885
US-11883393-B2 Compounds and methods for the targeted degradation of androgen receptor AR, KLK3, ACP3 GPR119 1278/4885MAPT 2786/4885SMN1; SMN2 4176/4885
US-20210196710-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, KLK3, ACP3 GPR119 1278/4885MAPT 2786/4885SMN1; SMN2 4176/4885
US-20240131023-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, KLK3, ACP3 GPR119 1278/4885MAPT 2786/4885SMN1; SMN2 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.